323 related articles for article (PubMed ID: 28732021)
1. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
Chan HS; de Blois E; Morgenstern A; Bruchertseifer F; de Jong M; Breeman W; Konijnenberg M
PLoS One; 2017; 12(7):e0181473. PubMed ID: 28732021
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
[TBL] [Abstract][Full Text] [Related]
3. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.
Melis M; Forrer F; Capello A; Bijster M; Bernard BF; Reubi JC; Krenning EP; De Jong M
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):324-33. PubMed ID: 17923824
[TBL] [Abstract][Full Text] [Related]
4. Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.
Capello A; Krenning EP; Breeman WA; Bernard BF; Konijnenberg MW; de Jong M
Cancer Biother Radiopharm; 2003 Oct; 18(5):761-8. PubMed ID: 14629824
[TBL] [Abstract][Full Text] [Related]
5. [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.
Kwekkeboom DJ; Bakker WH; Kooij PP; Konijnenberg MW; Srinivasan A; Erion JL; Schmidt MA; Bugaj JL; de Jong M; Krenning EP
Eur J Nucl Med; 2001 Sep; 28(9):1319-25. PubMed ID: 11585290
[TBL] [Abstract][Full Text] [Related]
6. In vitro evaluation of 213Bi-rituximab versus external gamma irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage.
Vandenbulcke K; De Vos F; Offner F; Philippé J; Apostolidis C; Molinet R; Nikula TK; Bacher K; de Gelder V; Vral A; Lahorte C; Thierens H; Dierckx RA; Slegers G
Eur J Nucl Med Mol Imaging; 2003 Oct; 30(10):1357-64. PubMed ID: 12845484
[TBL] [Abstract][Full Text] [Related]
7. 111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Capello A; Krenning E; Bernard B; Reubi JC; Breeman W; de Jong M
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1288-95. PubMed ID: 16021448
[TBL] [Abstract][Full Text] [Related]
8. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
Nayak T; Norenberg J; Anderson T; Atcher R
Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581
[TBL] [Abstract][Full Text] [Related]
9. Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent
Goetz TI; Lang EW; Prante O; Maier A; Cordes M; Kuwert T; Ritt P; Schmidkonz C
Ann Nucl Med; 2020 Apr; 34(4):244-253. PubMed ID: 32114682
[TBL] [Abstract][Full Text] [Related]
10. Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.
Bakker WH; Breeman WA; Kwekkeboom DJ; De Jong LC; Krenning EP
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):265-71. PubMed ID: 17043624
[TBL] [Abstract][Full Text] [Related]
11. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
12. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
[TBL] [Abstract][Full Text] [Related]
13. [177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy.
de Jong M; Breeman WA; Bernard BF; Bakker WH; Schaar M; van Gameren A; Bugaj JE; Erion J; Schmidt M; Srinivasan A; Krenning EP
Int J Cancer; 2001 Jun; 92(5):628-33. PubMed ID: 11340564
[TBL] [Abstract][Full Text] [Related]
14. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
[TBL] [Abstract][Full Text] [Related]
15. Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.
Verwijnen S; Capello A; Bernard B; van den Aardweg G; Konijnenberg M; Breeman W; Krenning E; de Jong M
Cancer Biother Radiopharm; 2004 Jun; 19(3):285-92. PubMed ID: 15285875
[TBL] [Abstract][Full Text] [Related]
16. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
17. Uptake kinetics of the somatostatin receptor ligand [86Y]DOTA-DPhe1- Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue.
Rösch F; Herzog H; Stolz B; Brockmann J; Köhle M; Mühlensiepen H; Marbach P; Müller-Gärtner HW
Eur J Nucl Med; 1999 Apr; 26(4):358-66. PubMed ID: 10199941
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0,Tyr3] octreotide and [DOTA0,Tyr3] octreotide as carriers for somatostatin receptor-targeted scintigraphy and radionuclide therapy.
De Jong M; Bakker WH; Breeman WA; Bernard BF; Hofland LJ; Visser TJ; Srinivasan A; Schmidt M; Béhé M; Mäcke HR; Krenning EP
Int J Cancer; 1998 Jan; 75(3):406-11. PubMed ID: 9455802
[TBL] [Abstract][Full Text] [Related]
19. The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Breeman WA; van der Wansem K; Bernard BF; van Gameren A; Erion JL; Visser TJ; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Feb; 30(2):312-5. PubMed ID: 12552352
[TBL] [Abstract][Full Text] [Related]
20. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model.
Schmitt A; Bernhardt P; Nilsson O; Ahlman H; Kölby L; Maecke HR; Forssell-Aronsson E
J Nucl Med; 2004 Sep; 45(9):1542-8. PubMed ID: 15347722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
